BiotechTube
Gentian USA

Gentian USA

Moss, Norway· Est.
gentian.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Gentian Diagnostics is a commercial-stage IVD company leveraging its proprietary Particle-Enhanced Turbidimetric Immunoassay (PETIA) technology to create efficient, automated diagnostic tests. Its strategy focuses on moving specialized, often manual immunoassays onto high-throughput clinical chemistry analyzers, offering labs faster turnaround times and cost savings without new capital investment. With a portfolio centered on high-demand biomarkers like Cystatin C and Calprotectin, and a global reach through OEM and distributor partners, Gentian is positioned in growing segments of kidney disease, inflammation, and veterinary diagnostics.

Kidney DiseaseInflammationInfectionCardiac DiseaseVeterinary Medicine

Technology Platform

Proprietary Particle-Enhanced Turbidimetric Immunoassay (PETIA) technology using nanoparticles to develop immunoassays that run on open-channel, automated clinical chemistry analyzers, enabling random-access, high-throughput testing.

Opportunities

The global push for laboratory efficiency and cost-saving creates strong demand for tests that consolidate workflows onto high-throughput clinical chemistry analyzers.
Expansion of clinical guidelines recommending Cystatin C for kidney function and growing evidence for calprotectin in sepsis management represent significant market growth drivers.
The company's IVDR compliance provides a competitive advantage in Europe and a template for other regulated markets.

Risk Factors

Gentian faces intense competition from large, entrenched IVD manufacturers with greater resources.
The business is subject to stringent and evolving global regulatory landscapes, where compliance failures could be catastrophic.
Revenue dependence on OEM and distribution partners introduces vulnerability to partner strategy changes or conflicts.

Competitive Landscape

Gentian competes in the niche of open-channel immunoassays against companies like DiaSys and other specialty reagent suppliers, but its primary competition comes from the large integrated IVD players (Roche, Siemens Healthineers, Abbott, Beckman Coulter) who control the analyzer platforms and promote their own proprietary, closed-system immunoassays. Gentian's differentiation lies in offering platform-agnostic assays that provide labs with flexibility and cost savings compared to these locked-in systems.

More companies in Diagnostics & Precision Medicine →More companies in Norway →